Journal article
Treatment of Primary Biliary Cholangitis First-Line and Second-Line Therapies
CLINICS IN LIVER DISEASE, v 26(4), p705
Nov 2022
PMID: 36270725
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
All patients with PBC should be treated with UDCA at 13 to 15 mg/kg/d and monitored for a biochemical response using any of the available criteria and considering the disease stage. If there is an incomplete response to UDCA, then second-line therapies should be considered, namely OCA. If OCA is not tolerated or otherwise contraindicated, growing evidence supports the use of bezafibrate but its safety and dosing has not been firmly established and it is not available in the United States at this time. Data supporting the use of fenofibrate is limited but likely of similar efficacy. Importantly, the use of OCA or fibrates in advanced or decompensated cirrhosis should be avoided. For the small number of patients intolerant of UDCA, these second-line agentsmay also be considered. For those patients still not achieving an adequate response to dual therapy, triple therapy may have a benefit but further studies are required.
Metrics
Details
- Title
- Treatment of Primary Biliary Cholangitis First-Line and Second-Line Therapies
- Publication Details
- CLINICS IN LIVER DISEASE, v 26(4), p705
- Publisher
- W B SAUNDERS CO-ELSEVIER INC; PHILADELPHIA
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Drexel University
- Web of Science ID
- WOS:000877183600011
- Scopus ID
- 2-s2.0-85138093096
- Other Identifier
- 991021861168604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Gastroenterology & Hepatology